[go: up one dir, main page]

WO2008152537A3 - Anticorps monoclonaux humanisés dirigés contre le récepteur du facteur de croissance épidermique humain, leur utilisation, et procédé correspondant - Google Patents

Anticorps monoclonaux humanisés dirigés contre le récepteur du facteur de croissance épidermique humain, leur utilisation, et procédé correspondant Download PDF

Info

Publication number
WO2008152537A3
WO2008152537A3 PCT/IB2008/052038 IB2008052038W WO2008152537A3 WO 2008152537 A3 WO2008152537 A3 WO 2008152537A3 IB 2008052038 W IB2008052038 W IB 2008052038W WO 2008152537 A3 WO2008152537 A3 WO 2008152537A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
mabs
humanized
humanized monoclonal
studies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/052038
Other languages
English (en)
Other versions
WO2008152537A2 (fr
Inventor
Mitali Samaddar
Kemburu Prasanna Kumar
Gosala Jaya Lakshmi
Chigurupati Jayaram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zenotech Laboratories Ltd
Original Assignee
Zenotech Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenotech Laboratories Ltd filed Critical Zenotech Laboratories Ltd
Publication of WO2008152537A2 publication Critical patent/WO2008152537A2/fr
Anticipated expiration legal-status Critical
Publication of WO2008152537A3 publication Critical patent/WO2008152537A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux humanisés conçus, créés et produits au moyen d'une série de processus novateurs impliquant l'analyse computationnelle, études de modélisation, vérification et sélection rationnelle de séquences humanisées, un système efficace d'expression d'ADN recombinant et des études fonctionnelles visant à connaître en profondeur les propriétés des anticorps monoclonaux. L'invention propose également un processus économique et d'envergure variable permettant de produire de grandes quantités d'anticorps monoclonaux et de s'appliquer au traitement de maladies humaines telles que le cancer. L'invention concerne enfin ensemble de référence d'anticorps monoclonaux humanisés de l'invention dirigés contre le récepteur du facteur de croissance épidermique humain, agissant comme antagonistes des récepteur, et sensiblement non immunogènes.
PCT/IB2008/052038 2007-06-14 2008-05-23 Anticorps monoclonaux humanisés dirigés contre le récepteur du facteur de croissance épidermique humain, leur utilisation, et procédé correspondant Ceased WO2008152537A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1236CH2007 2007-06-14
IN1236/CHE/2007 2007-06-14

Publications (2)

Publication Number Publication Date
WO2008152537A2 WO2008152537A2 (fr) 2008-12-18
WO2008152537A3 true WO2008152537A3 (fr) 2010-04-08

Family

ID=40130263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/052038 Ceased WO2008152537A2 (fr) 2007-06-14 2008-05-23 Anticorps monoclonaux humanisés dirigés contre le récepteur du facteur de croissance épidermique humain, leur utilisation, et procédé correspondant

Country Status (1)

Country Link
WO (1) WO2008152537A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP6181089B2 (ja) 2012-03-08 2017-08-16 ハロザイム インコーポレイテッド 条件依存活性抗上皮細胞増殖因子受容体抗体およびその使用方法
KR20160055253A (ko) 2013-09-12 2016-05-17 할로자임, 아이엔씨 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114146A (en) * 1994-11-14 2000-09-05 Baxter Aktiengesellschaft Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition
US6602684B1 (en) * 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114146A (en) * 1994-11-14 2000-09-05 Baxter Aktiengesellschaft Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition
US6602684B1 (en) * 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROGUSKA ET AL.: "Humanization of murine monoclonal antibodies through variable domain resurfacing", PNAS, vol. 91, 1994, pages 969 - 973, XP002271704, DOI: doi:10.1073/pnas.91.3.969 *

Also Published As

Publication number Publication date
WO2008152537A2 (fr) 2008-12-18

Similar Documents

Publication Publication Date Title
NL301196I2 (nl) inebilizumab
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PH12015500782A1 (en) Human cytomegalovirus neutralizing antibodies and use thereof
WO2006099875A8 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
NZ588674A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
LTC1504035I2 (lt) Antikūnai, specifiški žmogaus cd22, ir jų terapinis bei diagnostinis panaudojimas
WO2011147982A3 (fr) Anticorps monoclonaux contre l'épitope de her2
PH12018502623B1 (en) Anti-pd-l1 antibodies and uses thereof
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
NZ591471A (en) Antibodies to ccr2
NZ610734A (en) Human antibodies to the glucagon receptor
WO2005012493A3 (fr) Anticorps anti-cd19
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
WO2008066691A3 (fr) Tes7, et anticorps se liant à celui-ci
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
EP3539988A3 (fr) Anticorps monoclonaux contre her2
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
MY157173A (en) Modified humanised anti-interleukin-18
WO2006089133A3 (fr) Anticorps anti-cd19 et leur utilisation en oncologie
WO2011044311A3 (fr) Génération, caractérisation et utilisations d'anticorps anti-her3
DOP2009000221A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente a cd154 y sus usos
WO2010066803A3 (fr) Anticorps humains du facteur tissulaire
WO2011143624A3 (fr) Anticorps monoclonaux anti-cd47 humanisés et chimères
CY1115349T1 (el) Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751313

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08751313

Country of ref document: EP

Kind code of ref document: A2